[Click eStock] "Seegene, Full-Year Sales Expected to Increase 24% YoY... Stock Price Too Cheap"

[Asia Economy Reporter Ji-hwan Park] Hana Financial Investment evaluated on the 16th that "Although full-scale vaccination is underway, vaccines will not eradicate the COVID-19 virus in a short period," and it is time to consider buying at the bottom for Seegene.

Minjeong Seon, a researcher at Hana Financial Investment, stated, "Seegene's cumulative sales on a consolidated basis for January and February amounted to 223.6 billion KRW, which is about 8 times higher compared to the cumulative sales of 29 billion KRW during the same period last year."

Despite such strong performance, the stock price has not been able to avoid weakness. Researcher Seon said, "As COVID-19 vaccination is increasing worldwide, there are concerns that the demand for diagnostic kits will significantly decrease with the end of the COVID-19 pandemic," adding, "Even after various shareholder-friendly policies were announced, the stock price has not easily rebounded."

However, it is diagnosed that Germany and Italy have once again entered a phase of COVID-19 virus spread, and concerns about a third wave of resurgence in Europe are becoming a reality. European countries, which had eased restrictions as vaccinations expanded and confirmed cases decreased, are strengthening quarantine measures again. On the 13th, the actual daily confirmed cases in Europe surged to 181,707, nearly doubling from 96,879 cases per day. The cause of the increase is attributed to the spread of the more transmissible UK-origin variant virus, and there are concerns that if this spread is not controlled, various lockdown measures will be implemented.

Researcher Seon said, "Vaccines will not eradicate the virus in a short time," and added, "Considering that Seegene's sales are expected to increase by about 24% compared to last year, the current stock price is too cheap even if it is considered cheap."

This content was produced with the assistance of AI translation services.